Physicochemical compatibility and stability of nebulizable drug admixtures containing dornase alfa and tobramycin

Pulmonary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2014, Pages 53-59

  Klemmer, Anja ^a   Krämer, Irene ^a   Kamin, Wolfgang ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Pediatric Department   (Germany)

Author keywords

Admixture; Aerodynamic parameters; Dornase alfa; Nebulization; Stability; Tobramycin

Indexed keywords

BRAMITOB; DORNASE ALFA; TOBRAMYCIN; UNCLASSIFIED DRUG; AEROSOL; ANTIINFECTIVE AGENT; DEOXYRIBONUCLEASE I; DRUG COMBINATION; RECOMBINANT PROTEIN; SOLUTION AND SOLUBILITY;

AEROSOL; ARTICLE; DRUG MIXTURE; DRUG STABILITY; DRUG STORAGE; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; NEBULIZATION; OSMOLALITY; PARTICLE SIZE; PH; PHYSICAL CHEMISTRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; ROOM TEMPERATURE; ULTRAVIOLET SPECTROSCOPY; CHEMISTRY; DRUG COMBINATION; DRUG INCOMPATIBILITY; FEASIBILITY STUDY; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; OSMOLARITY; SOLUTION AND SOLUBILITY; TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ANTI-BACTERIAL AGENTS; DEOXYRIBONUCLEASE I; DRUG COMBINATIONS; DRUG INCOMPATIBILITY; DRUG STABILITY; DRUG STORAGE; FEASIBILITY STUDIES; HYDROGEN-ION CONCENTRATION; NEBULIZERS AND VAPORIZERS; OSMOLAR CONCENTRATION; PARTICLE SIZE; PHARMACEUTICAL SOLUTIONS; RECOMBINANT PROTEINS; TIME FACTORS; TOBRAMYCIN;

EID: 84900545521     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.08.003     Document Type: Article

References (26)

1. Proesmans M., Vermeulen F., De B.K. What's new in cystic fibrosis? from treating symptoms to correction of the basic defect. Eur J Pediatr 2008, 167(8):839-849.
2. O'Sullivan B.P., Freedman S.D. Cystic fibrosis. Lancet 2009, 373(9678):1891-1904.
3. Flume P.A., O'Sullivan B.P., Robinson K.A., Goss C.H., Mogayzel P.J., Willey-Courand D.B., et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007, 176(10):957-969.
4. Kramer I., Schwabe A., Lichtinghagen R., Kamin W. Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions. Pediatr Pulmonol 2009, 44(2):134-141.
5. Kamin W., Schwabe A., Kramer I. Physicochemical compatibility of fluticasone-17-propionate nebulizer suspension with ipratropium and albuterol nebulizer solutions. Int J Chron Obstruct Pulmon Dis 2007, 2(4):599-607.
6. Kramer I., Schwabe A., Lichtinghagen R., Kamin W. Physicochemical compatibility of nebulizable drug mixtures containing dornase alfa and ipratropium and/or albuterol. Pharmazie 2007, 62(10):760-766.
7. Kamin W., Schwabe A., Kramer I. Inhalation solutions: which one are allowed to be mixed? physico-chemical compatibility of drug solutions in nebulizers. J Cyst Fibros 2006, 5(4):205-213.
8. Pilcer G., Vanderbist F., Amighi K. Correlations between cascade impactor analysis and laser diffraction techniques for the determination of the particle size of aerosolised powder formulations. Int J Pharm 2008, 358(1-2):75-81.
9. Chen B., Costantino H.R., Liu J., Hsu C.C., Shire S.J. Influence of calcium ions on the structure and stability of recombinant human deoxyribonuclease I in the aqueous and lyophilized states. J Pharm Sci 1999, 88(4):477-482.
10. Cipolla D., Gonda I., Shire S.J. Characterization of aerosols of human recombinant deoxyribonuclease I (rhDNase) generated by jet nebulizers. Pharm Res 1994, 11(4):491-498.
11. Europäisches Arzneibuch 2008, Deutscher Apotheker Verlag, Stuttgart. 6th ed.
12. ExPASy 17-11-2011, Swiss Institute of Bioinformatics. http://www.expasy.ch/tools/ptotparam.html.
13. DrugBank Dornase alfa 17-11-2011, http://drugbank.ca/drugs/DB00003.
14. Scherer T., Geller D.E., Owyang L., Tservistas M., Keller M., Boden N., et al. A technical feasibility study of dornase alfa delivery with eFlow(R) vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 2011, 100(1):98-109.
15. Cacia J., Quan C.P., Vasser M., Sliwkowski M.B., Frenz J. Protein sorting by high-performance liquid chromatography. I. Biomimetic interaction chromatography of recombinant human deoxyribonuclease I on polyionic stationary phases. J Chromatogr 1993, 634(2):229-239.
16. Monitoring monoclonal antibody stability by cation-exchange chromatography 8-11-2011, http://www.dionex.de.
17. Wakankar A.A., Borchardt R.T. Formulation considerations for proteins susceptible to asparagine deamidation and aspartate isomerization. J Pharm Sci 2006, 95(11):2321-2336.
18. Dennis J., Berg E., Sandell D., Ali A., Lamb P., Tservistas M., et al. Cooling the NGI-an approach to size a nebulised aerosol more accurately. Pharmeur Sci Notes 2008, 2008(1):27-30.
19. Berlinski A., Hayden J.B. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010, 23(6):397-404.
20. Law S. Stability of preservative-free tobramycin in half-normal saline. Can J Hosp Pharm 2011, 54(3):214-215.
21. Mach H., Middaugh C.R., Denslow N. Determining the identity and purity of recombinant proteins by UV absorption spectroscopy. Curr Protoc Protein Sci 2001, [Chapter 7]:Unit 7.2.:Unit.
22. Shire S.J. Stability characterization and formulation development of recombinant human deoxyribonuclease I [Pulmozyme, (dornase alpha)]. Pharm Biotechnol 1996, 9:393-426.
23. Physician's information: inhalation therapy with eFlow rapid 17-11-2011, http://www.pari.de.
24. Waldrep J.C., Berlinski A., Dhand R. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aerosol Med 2007, 20(3):310-319.
25. Johnson J.C., Waldrep J.C., Guo J., Dhand R. Aerosol delivery of recombinant human DNase I: in vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. Respir Care 2008, 53(12):1703-1708.
26. Dentice R., Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2011, 5:CD007923.